- Home
- HCM vs XNCR Comparison
HCM vs XNCR Comparison
Compare HCM & XNCR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | HCM | XNCR |
|---|---|---|
| Founded | 2000 | 1997 |
| Country | Hong Kong | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.3B | 2.0B |
| IPO Year | 2015 | 2013 |
Fundamental Metrics
Financial Performance| Metric | HCM | XNCR |
|---|---|---|
| Price | $13.27 | $29.82 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 12 | 14 |
| Target Price | $20.59 | ★ $41.58 |
| AVG Volume (30 Days) | 37.8K | ★ 1.5M |
| Earning Date | 07-30-2026 | 11-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 65.36 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $125,576,000.00 |
| Revenue This Year | $14.24 | $18.52 |
| Revenue Next Year | $11.52 | N/A |
| P/E Ratio | $5.49 | ★ N/A |
| Revenue Growth | N/A | ★ 13.65 |
| 52 Week Low | $9.77 | $10.38 |
| 52 Week High | $16.33 | $33.60 |
Technical Indicators
Market Signals| Indicator | HCM | XNCR |
|---|---|---|
| Relative Strength Index (RSI) | 41.46 | 65.50 |
| Support Level | $13.00 | $22.80 |
| Resistance Level | $15.10 | $30.61 |
| Average True Range (ATR) | 0.36 | 1.71 |
| MACD | -0.14 | 0.59 |
| Stochastic Oscillator | 3.85 | 61.74 |
Price Performance
Historical ComparisonAbout HCM HUTCHMED (China) Limited
HUTCHMED (China) Ltd is a biopharmaceutical company engaged in the discovery, development, and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. The company has a portfolio of several cancer drug candidates currently in clinical studies world-wide and an extensive commercial infrastructure in its home market, China. The company operates in two reportable segments: Oncology/Immunology and Other Ventures.
About XNCR Xencor Inc.
Xencor Inc is a clinical-stage biopharmaceutical company focused on discovering and developing engineered antibody therapeutics to treat patients with cancer and autoimmune diseases. The company uses its XmAb technology platform to create antibody product candidates. Its pipeline includes XmAb819, XmAb541, XmAb808, XmAb942, Plamotamab and XmAb657. The group earns its revenue from collaboration agreements and licensing agreements and operates as a single reportable segment focused on discovering and developing engineered antibody therapeutics to treat patients with cancer and autoimmune diseases who have unmet medical needs.